IM Cannabis Corp. (IMCC) AI Stock Analysis

IM Cannabis Corp., headquartered in Tel Aviv-Yafo, Israel, specializes in the breeding, cultivation, and distribution of medical cannabis products across Israel, Germany, and Canada. The company offers cannabis flowers and strain-specific extracts marketed under the IMC brand. Additionally, it provides dried flowers, pre-rolls, and pressed hash products through its WAGNERS and Highland Grow brands, catering to both medical patients and adult-use recreational consumers. IM Cannabis Corp. operates cultivation, product development, and distribution channels to provide therapeutic and recreational cannabis solutions.

IM Cannabis Corp. grew revenue from $34.1M in FY2021 to $54.3M in FY2022, before declining to $48.8M in FY2023. Revenue recovered to $54.0M in FY2024 and reached $54.7M in FY2025, representing a 5-year revenue CAGR of 28.1% from FY2020 to FY2025. However, net losses persisted each year, including -$188.9M in FY2022 and -$11.3M in FY2025, with an operating margin of -21.2%. Gross margin stood at 17.7% in FY2025. In the latest quarter ended June 30, 2026, quarterly revenue fell 40.2% year-over-year, bringing trailing twelve-month revenue to $45.8M and profit margin to -39.1%.

As of June 30, 2026, IM Cannabis Corp. held $1.7M in cash and short-term investments against total debt of $13.9M, resulting in net debt of $12.1M. The company exhibits negative shareholders' equity of -$5.5M, total assets of $24.7M, and a current ratio of 0.56. Operating cash flow turned positive at $4.7M in FY2025 with free cash flow of $4.7M and capital expenditures of $13,000. Over five years, the share count expanded by 24415.9%.

IM Cannabis Corp. trades at an enterprise value of $10.4M and a market capitalization of $2.3M. The company trades at a forward P/E of 42.4x, above the 17.3x median of its US-listed Healthcare peers. Its price-to-sales ratio of 0.1x and EV-to-EBITDA ratio of 4.6x compare to peer medians of 4.1x and 12.0x, respectively. The stock's last close was $1.39 on October 16, 2026, down 97.6% over the past year and down 100.0% over five years, underperforming the S&P 500 benchmark return of 16.8% over one year and 83.0% over five years.

Analysts maintain a mean price target of $8.22 for IM Cannabis Corp., representing an upside of 491.4% above the last close of $1.39. For the next fiscal year, analysts estimate revenue of $87.9M, representing expected revenue growth of 12.8%, alongside an EPS estimate of $0.00. IM Cannabis Corp. beat EPS estimates in 3 of the last 4 quarters. The next earnings date is scheduled for November 12, 2026.

This page is an AI-written research summary of IM Cannabis Corp. (IMCC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: IMCC income statement, IMCC balance sheet, IMCC key metrics, IMCC analyst forecast, IMCC chart. See the IMCC stock overview for the latest quote and news.